Bladder cancer decisions — 2025

The Board granted service connection for bladder cancer due to herbicide agent exposure on a facts-found basis, as the Veteran served at U-Tapao Royal Thai Air Force Base during the Vietnam Era and had duties that placed him near the base perimeter where herbicides were used.

The Board denied service connection for pseudofolliculitis barbae, skin rash disability, bilateral eye disability, and bladder cancer as the evidence of record did not support a finding that these conditions were incurred in or aggravated by active military service.

The Board granted an initial rating of 60 percent for service-connected CAD and denied increased ratings for other conditions.

The Board granted service connection for bladder cancer status post cancerous polypectomy with an earlier effective date of January 30, 2017, and granted initial ratings for left and right lower extremity restless leg syndrome at 20 percent. PTSD was granted increased ratings to 50 percent from February 21, 2017 to July 20, 2023, and to 70 percent from July 20, 2023. The claim for service connection for benign colon polyps was denied.

The Board remands the service connection claims for coronary artery disease, bladder tumor, and peripheral neuropathy of both upper and lower extremities to correct duty to assist errors related to toxic exposure risk activities during active service.

The Board granted an earlier effective date of February 21, 2024, for the grant of service connection for bladder cancer but denied a compensable rating during the period on appeal.

The appeal for service connection for bladder cancer has been withdrawn by the Veteran.

The Board denied service connection for a bilateral ankle disorder, DMII, heart disorder, right shoulder disorder, hypertension, low back disorder, bladder cancer, and left and right lung disease as the weight of the evidence did not support a finding that any of these conditions were related to the Veteran's active duty service.

The Board remands the claims for service connection for an acquired psychiatric disability and increased evaluation for residuals, malignant neoplasm-in remission, voiding dysfunction due to a duty to assist error.

The Board denied the veteran's claims for increased ratings, eligibility for specially adaptive housing and a special home adaptation grant, and remanded several service connection claims.

The Board remands the claim for further development to verify whether the Veteran was exposed to herbicide agents during his service in Korea.

The Board remands the claims for service connection for bladder cancer, diabetes mellitus, type II, and prostate cancer due to a need for further development of evidence.

The appeal for service connection for ischemic heart disease and bladder cancer was dismissed as the appeals were not timely filed.

The Board denied a separate 100 percent rating for prostate cancer and special monthly compensation (SMC) at the housebound rate.

The Veteran's service-connected residuals of bladder cancer are granted a disability rating of 60 percent, effective October 1, 2021.

The Board granted a disability rating of 100 percent from July 1, 2023, to July 31, 2023, for service-connected bladder cancer residuals and denied a compensable disability rating from August 1, 2023.

The Board dismissed the appeal regarding a proposed reduction in the disability rating for bladder cancer and denied entitlement to a compensable disability rating for erectile dysfunction.

The Board remands the claims for a higher rating for residuals of bladder cancer and TDIU due to insufficient evidence.

The Board remands the claim for service connection for post-op bladder cancer with residuals to verify in-service asbestos exposure.

The Board granted service connection for a total hysterectomy secondary to service-connected bladder cancer and special monthly compensation based on loss of use of a creative organ, but remanded the claim for service connection for migraines.